Skip to main content
. 2018 Aug 24;97(34):e11963. doi: 10.1097/MD.0000000000011963

Figure 1.

Figure 1

Comparison of CYR61 RNA-seq expression level based on FLT3 mutation status (A), PML/RAR-fusion status (B), RAS activation status (C), and French–American–British classification (D) in the Cancer Genome Atlas samples. ∗P < .05.